Research demonstrates importance of registries for medical devices

FDA-funded research by the Kaiser Permanente and Weill Cornell Medical College highlights the importance of registries and unique device identification implementation for post-market surveillance of medical devices.

The researchers analyzed data from a collaboration among two U.S. registries and registries in AustraliaSpainItalySweden and Norway to examine the performance and safety of hip and knee implants.

The registries, part of the International Consortium of Orthopedic Registries (ICOR), are part of efforts to identify gaps in evidence related to implants, according to Kaiser Permanente. ICOR’s real-world device data for performance in all settings and for all demographics can be identified and provided to surgeons and patients to determine the best implant for the patient, according to the study.

"In orthopedics, large registries or networks of registries capture device information on a very detailed level and can become particularly important for active surveillance and post-market evaluation," said Art Sedrakyan, the principal investigator of the FDA contract and associate professor of healthcare policy and research at Weill Cornell Medical College, in a statement. "Comparative studies of hip and knee devices illustrate the ability of a registry consortium to determine real-world evidence for various classes of devices and help surgeons and patients to make evidence-based choices."

Read Kaiser Permanente's policy brief.

 

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.